Hi Max,
It sounds to me that a "major" news at this stage can only be some kind of meaningful initiative which will bring some kind of revenue to this company. After coming back from the brink of bankruptcy, investors, including myself, will not have much faith in "promises" or "positive test results" of their technology etc. For myself , I am holding this stock until I see it go above one dollar (or even more) again. As long time investors of RCG will remember ,this stock was trading in the 1.20-1.70 range about a year ago. Except for their recent financial troubles, they are much more closer to real revenue generation now than they were last year. Secondly, a biotech company at this stage of research is typically valued between $50-100 Million . RCG's current market valuation is less then $25 million ( they should now have about 50 Million shares outstanding ,including the recent issue of about 25 million new shares to their creditors- or "vultures", if you like) . Good luck to all of us. It is nice to see such a strong interest in a not-so-known company.
Let's keep our fingers crossed, and hope the news comes as we expect.
Andre |
